Page 224 - Multidisipliner Covid 19

BÖLÜM 12

2019 (COVID-19). Drug Discoveries & Therapeutics. 2020;14(1):58-60.
DOI: 10.5582/ddt.2020.01012.
44. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized
patients with 2019 novel coronavirus-infected pneumonia in Wuhan,
China. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585.
45. ClinicalTrials.gov. [Internet]. [erişim 18 Mart 2020].https://clinicaltrials.
gov/.
46. Lu S, Zhou Q, Huang L, et al. Effectiveness and Safety of Glucocorticoids
to Treat COVID-19: A Rapid Review and Meta- Analysis. medrxiv.2020;
04(17):20064469.
47. Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids
therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther.
2020;5(1):18.
48. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus
cases in tertiary hospitals in Hubei Province. Chin Med J. 2020. https://
doi.org/10.1097/CM9.0000000000000744.
49. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment
effects. PLoS Med. 2006;3(9):e343. doi:10.1371/journal.pmed.0030343.
50. Arabi YM, Mandourah Y, Al-Hameed F, et al. Saudi Critical Care Trial
Group. Corticosteroid therapy for critically ill patients with Middle
East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-
767. doi:10.1164/rccm.201706-1172OC.
51. Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids
on mortality of patients with influenza pneumonia: a systematic review
and meta-analysis. Crit Care. 2019;23(1):99. doi:10.1186/ s13054-019-
2395-8.
52. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395
(10223):473-475. doi:10.1016/S0140-6736(20) 30317-2.
53. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ;
HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine
storm syndromes and immunosuppression. Lancet. 2020;395(10229):
1033-1034. doi:10.1016/S0140- 6736(20)30628-0).
54. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 pati-
ents with tocilizumab. chinaXiv. 2020;202003(00026):v1.doi:10.12074/
202003.00026.
55. Roumier M, Paule R, Groh M, Vallee A, Ackermann F. Interleukin-6

223